共 50 条
- [41] The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) TransfusionsBLOOD, 2018, 132Fenaux, PierrePlatzbecker, UweMufti, Ghulam J.Garcia-Manero, GuillermoBuckstein, RenaSantini, ValeriaDiez-Campelo, MariaFinelli, CarloCazzola, MarioIlhan, OsmanSekeres, Mikkael A.Falantes, Jose F.Arrizabalaga, BeatrizSalvi, FlaviaGiai, ValentinaVyas, PareshBowen, DavidSelleslag, DominikDeZern, Amy E.Jurcic, Joseph G.Germing, UlrichGoetze, Katharina S.Quesnel, BrunoBeyne-Rauzy, OdileCluzeau, ThomasVoso, Maria TeresaMazure, DominiekVellenga, EdoGreenberg, Peter L.Hellstrom-Lindberg, EvaZeidan, Amer M.Laadem, AbderrahmaneBenzohra, AzizZhang, JennieRampersad, AnitaLinde, Peter G.Sherman, Matthew L.Komrokji, Rami S.List, Alan F.
- [42] Luspatercept versus epoetin alfa (EA) for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions (RBCT): data from the phase 3 COMMANDS studyONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 116 - 116Platzbecker, UwePorta, Matteo GiovanniSantini, ValeriaZeidan, Amer M.Fenaux, PierreKomrokji, Rami S.Shortt, JakeValcarcel, DavidJonasova, AnnaDimicoli-Salazar, SophieTiong, Ing SooLin, Chien-ChinLi, JiahuiZhang, JennieGiuseppi, Ana CarolinaKreitz, SandraPozharskaya, VeronikaKeeperman, Karen L.Rose, ShelonitdaShetty, Jeevan K.Hayati, SheidaVodala, SadanandDegulys, AndriusPaolini, StefaniaCluzeau, ThomasGarcia-Manero, Guillermo
- [43] Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST StudyBLOOD, 2021, 138Platzbecker, UweSantini, ValeriaKomrokji, Rami S.Zeidan, Amer M.Garcia-Manero, GuillermoBuckstein, Rena J.Rose, ShelonitdaFabre, ShannonMiteva, DimanaZhang, JennieYucel, AylinHughes, ChristinaFenaux, Pierre
- [44] Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS StudyONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 16 - 17Platzbecker, U.Della Porta, M. G.Santini, V.Zeidan, A. M.Fenaux, P.Komrokji, R. S.Shortt, J.Valcarcel, D.Jonasova, A.Dimicoli-Salazar, S.Tiong, I. S.Lin, C. -C.Li, J.Zhang, J.Giuseppi, A. C.Kreitz, S.Pozharskaya, V.Keeperman, K. L.Rose, S.Shetty, J. K.Hayati, S.Vodala, S.Degulys, A.Paolini, S.Cluzeau, T.Garcia-Manero, G.
- [45] Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension studyLANCET ONCOLOGY, 2017, 18 (10): : 1338 - 1347Platzbecker, UweGerming, UlrichGoette, Katharina S.Kiewe, PhilippMayer, KarinChromik, JoergRadsak, MarkusWolff, ThomasZhang, XiaoshaLaadem, AbderrahmaneSherman, Matthew L.Attie, Kenneth M.Giagounidis, Aristoteles
- [46] Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Garcia-Manero, GuillermoPlatzbecker, UweSantini, ValeriaZeidan, Amer MethqalFenaux, PierreKomrokji, Rami S.Shortt, JakeValcarcel, DavidJonasova, AnnaDimicoli-Salazar, SophieTiong, Ing SooLin, Chien-ChinLi, JiahuiKreitz, SandraPozharskaya, VeronikaShetty, Jeevan K.Degulys, AndriusFinelli, CarloCluzeau, ThomasDella Porta, Matteo Giovanni
- [47] Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S355 - S356Garcia-Manero, GuillermoPlatzbecker, UweSantini, ValeriaZeidan, Amer M.Fenaux, PierreKomrokji, Rami S.Shortt, JakeValcarcel, DavidJonasova, AnnaDimicoli-Salazar, SophieTiong, Ing SooLin, Chien-ChinLi, JiahuiZhang, JennieGiuseppi, Ana CarolinaKreitz, SandraPozharskaya, VeronikaKeeperman, Karen L.Rose, ShelonitdaShetty, Jeevan K.Hayati, SheidaVodala, SadanandDegulys, AndriusPaolini, StefaniaCluzeau, ThomasDella Porta, Matteo
- [48] Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Raza, AzraMukherjee, SiddharthaEisenberger, AndrewMears, J. GregoryWilhelm, Francois
- [49] Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) TransfusionsBLOOD, 2019, 134Garcia-Manero, GuillermoMufti, Ghulam J.Fenaux, PierreBuckstein, RenaSantini, ValeriaDiez-Campelo, MariaFinelli, CarloCazzola, MarioIlhan, OsmanSekeres, Mikkael A.List, Alan F.Laadem, AbderrahmaneIto, RodrigoZhang, JennieRampersad, AnitaSinsimer, DanielLinde, Peter G.Platzbecker, UweKomrokji, Rami
- [50] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)LEUKEMIA RESEARCH, 2015, 39 : S60 - S61Santini, V.Almeida, A.Giagounidis, A.Groepper, S.Jonasova, A.Vey, N.Mufti, G. J.Buckstein, R.Mittelman, M.Platzbecker, U.Shpilberg, O.Ram, R.del Canizo, C.Gattermann, N.Ozawa, K.Risueno, A.MacBeth, K. J.Zhong, J.Seguy, F.Hoenekopp, A.Beach, C. L.Fenaux, P.